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In the ongoing search for promising 
cancer drugs, researchers often 
discover effective therapies 
before knowing precisely how 
they work. Such was the case with 
a class of chemotherapy drugs 
called topoisomerase inhibitors. 
Topoisomerases are enzymes that 
function during cell division, 
when a cell duplicates its genome 
and distributes identical copies to 
each daughter cell, pulling apart 
single (topoisomerase I) or double 
(topoisomerase II) strands of entwined 
DNA to make sure the replication 
machinery can access the genome. 
The enzymes then rejoin the broken 
strands to protect genomic integrity, 
as unrepaired strand breaks can 
release checks on cell growth and lead 
to cancer if cell death programs fail 
to  destroy the compromised cells. 
Topoisomerase inhibitors, commonly 
used to treat a wide range of cancers, 
appear to trigger cell death in tumor 
cells by blocking the enzyme’s ability to 
repair strand breaks.
In a new study, Paula Coelho et al. 
investigated the role of topoisomerase 
II (TOPO II) in a critically important 
step in the cell cycle—the separation 
of the duplicated chromosomes—
and made a surprising discovery. 
Not only does the enzyme ensure 
proper separation of the duplicated 
chromosomes—held in tightly bound 
pairs (called sister chromatids) until 
they separate—it also regulates an 
enzyme that inspects the fulcrum of 
the structural apparatus that pulls the 
chromosomes apart.
Several classes of proteins 
manipulate the replicated 
chromosomes in preparation for 
mitosis, when each genome is 
sequestered in its own nucleus. 
Condensins compress the chromatids 
into packets for easier handling, 
and organize an axial platform to 
support TOPO II activity. Cohesins 
tie the sister chromatids together 
for alignment and attachment to the 
mitotic spindle—a spider-like array of 
microtubule proteins—via specialized 
structures called kinetochores, 
protein complexes that bind the 
chromosome’s centromere to connect 
sister chromatids to the spindle. For 
chromosomes to segregate properly, 
sister kinetochores must hook up 
to microtubules from spindle poles 
oriented toward opposite poles. As 
soon as the chromosomes are properly 
aligned, cohesions must quickly release 
the sister chromatids to facilitate their 
hasty retreat to the opposite poles of 
the mitotic spindle. 
How the cell coordinates sister 
chromatid separation with the process 
of condensing and untangling 
chromosomal DNA has long puzzled 
researchers. Since TOPO II not only 
detaches DNA tangles but also appears 
to help centromeres maintain their 
structure, Coelho et al. suspected that 
the enzyme may play a coordinating 
role. To investigate this possibility, 
the researchers interfered with TOPO 
II activity in living cells by blocking 
expression of the enzyme with RNA 
interference (RNAi) and used high-
resolution, time-lapse fluorescent 
microscopy to track the process of 
mitosis in the cells to see what might go 
wrong.
In the first set of experiments, 
reducing TOPO II proteins to “barely 
detectable levels” seriously impaired 
sister chromatid segregation. To 
determine whether the TOPO 
II–related defects stemmed from 
problems with centromere function, 
the researchers depleted the enzyme 
in cells that expressed fluorescent 
tags on both chromosomal proteins 
(chromatin) and centromeres. 
Though chromosomes paired up 
normally in the TOPO II–depleted 
cells, sister chromatid centromeres 
misaligned, failed to split, and 
moved toward the same, rather than 
to opposite, poles. Furthermore, 
most sister kinetochores were 
inappropriately attached to the same 
spindle pole. When the researchers 
inhibited TOPO II activity after 
normal chromatid attachment to 
bipolar spindles, however, they saw 
no problems with kinetochore–
microtubule interactions. 
Taken together, these results 
show that without TOPO II, sister 
centromeres fail to separate, which 
in turn prevents chromosomes from 
orienting and segregating properly 
during mitosis. These defects 
appear to arise from dysregulation 
of a critical enzyme, Aurora B. The 
absence of TOPO II disrupts the 
proper localization and activity 
of Aurora B, which promotes 
the dismantling of inappropriate 
microtubule-kinetochore 
attachments. In control cells, Aurora 
B localizes to the inner centromere 
when the chromosomes attach to 
their spindles and then migrates 
toward the middle of the spindle 
poles as the chromatids are pulled 
apart. The researchers conclude 
that by detaching DNA tangles, 
TOPO II causes structural changes 
that organize the inner centromere 
in a way that promotes the normal 
activation and localization of the 
Aurora B regulatory complex, which 
then removes abnormal kinetochore-
microtubule attachments. 
Overexpression of Aurora B, 
which can lead to uncontrolled cell 
divisions with unequal chromosome 
distributions, is often detected in 
tumors. Cancer researchers have been 
investigating strategies to disrupt the 
enzyme by interfering with its binding 
or activation partners, though Aurora 
B inhibitors haven’t performed as 
well in the clinic as researchers had 
hoped. By revealing a link between 
Aurora B and TOPO II—the target of 
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A mitotic cell depleted of TOPO II 
showing chromatin (blue), centromeres 
(red), and spindle microtubules 
(green). Depletion of TOPO II results in 
syntelic kinetochore attachments (with 
kinetochores on the same spindle pole), 
non-disjunction, and highly reduced 
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some of the most widely used cancer 
drugs—this study not only sheds light 
on an essential cell cycle checkpoint 
mechanism. It also provides an 
intriguing and potentially important 
link between two important cancer 
drug targets. Researchers aren’t 
sure why topoisomerase inhibitors 
prove so effective on some tumors, 
but maybe they generate a one-two 
punch—by inhibiting topoisomerase, 
they indirectly target Aurora B. 
With new evidence of a dual role 
for a critical regulator of genomic 
integrity, researchers can further 
explore what cells need to safely 
navigate the rigors of mitosis, and 
identify new strategies to contain 
the damage that eludes the highly 
regulated checkpoints.
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